2006 annual report - wordpress.com...introduction the zimbabwe cancer registry (zcr) is pleased to...

PATTERN OF CANCER IN ZIMBABWE

ZIMBABWE NATIONAL CANCER

REGISTRY

2006 ANNUAL REPORT

PATTERN OF CANCER IN ZIMBABWE

ZIMBABWE NATIONAL CANCER

REGISTRY

2006 ANNUAL REPORT

Edited by

E. Chokunonga, M.Z. Borok, Z.M. Chirenje and A.M. Nyakabau

Harare, Zimbabwe April 2010

2

TABLE OF CONTENTS

Foreword…………………………………………………………………………... 4 Chairman’s statement ………………………………………………………….….. 5 Fig 1, Geographical location of Zimbabwe ……………………………………….. 6 Fig 2, Zimbabwe Cancer Registry Advisory Committee ……………………….. .. 7 Fig 3, Zimbabwe Cancer Registry Staff ………………………………………….. 7 Zimbabwe Cancer Registry……..…….……………………………………. ……... 8 Acknowledgements…………………………………………………………………. 9 Objectives of the Zimbabwe Cancer Registry………………………………………10 Material and methods….…………………………………………....……………… 11 Use of Cancer Registry data……………………………………………………….. 13 Results……………………………………………………………………………… 14 Discussion………………………………………………………………………….. 16 References…………………………………………………………………………. 18 Acronyms………………………………………………………………………….. 19 Publications………………………………………………………………………… 20 Table 1, Source of information of cancers recorded in 2006…………………….… 22 Table 2, Method of diagnosis of cancers recorded in 2006…………………………22 Figs 4-5, Incidence and mortality 2006……………………………………………. 23 Figs 6-7, Cervical and breast cancer, age distribution……………………………... 24 Figs 8-9, Kaposi sarcoma & prostate cancer, age distribution…..………………… 25 Figs 10-11, Non-Hodgkin lymphoma and eye cancers, age distribution …………. 26 Figs 12-13, Common cancers, Zimbabwean blacks………….……………………. 27 Table 3, Age distribution, Zimbabwean black males……………………………… 28 Table 4, Age distribution, Zimbabwean black females……………………………. 29 Figs 14-15, Common cancers, Zimbabwean non-blacks……….…………………. 30 Table 5, Age distribution, Zimbabwean non-black males………...………………. 31 Table 6, Age distribution, Zimbabwean non-black females………………………. 32 Figs 16-17, Common cancers, Zimbabwe all races……….…..…………………… 33 Table 7, Age distribution, Zimbabwe all races males……………………………… 34 Table 8, Age distribution, Zimbabwe all races females…………………………… 35 Figs 18-19, Common cancers, Harare blacks……………………………………… 36 Table 9, Age distribution, Harare black males……..……………………………… 37 Table 10, Age distribution, Harare black females…………………….………….. 38 Figs 20-21, Common cancers, Harare non-blacks………………………………… 39 Table 11, Age distribution, Harare non-black males……………………………… 40 Table 12, Age distribution, Harare non-black females……………….…………… 41 Figs 22-23, Common cancers, Harare all races…………………………………… 42 Table 13, Age distribution, Harare all races males………………………………… 43 Table 14, Age distribution, Harare all races females……………………………… 44 Figs 24-25, Common cancers, paediatrics………………………………………… 45 Annex 1, Cancer registry notification form….….....…….………………………… 46 Savanna Pharmaceuticals supporting the Zimbabwe Cancer Registry………….… 48

3

FOREWORD

In spite of the current challenges faced by the Registry, it is heartening to note that the ZCR has been able to produce and publish another annual report in less than a year. As mentioned in this report, the problem of staff has now been resolved following the engagement of new staff. Efforts are underway to revive the Bulawayo Cancer Registry (BCR). Revival of the BCR will result in an improvement in the reporting of national data and accurate estimation of the burden of cancer in Zimbabwe. Our major concern remains the continued decline in the number of new cancer registrations largely resulting from the ongoing problems facing the healthcare delivery system in Zimbabwe. Industrial action by health workers in public institutions due to poor conditions of service and the difficult economic climate obtaining in the country have resulted in the near collapse of the public healthcare system. The continuing support of certain organizations and individuals, both locally and internationally, during these troubled economic times is gratefully acknowledged. In particular, I would like to thank our traditional supporters, the International Agency for Research on Cancer, the International Association of Cancer Registries, the US National Cancer Institute and the World Health Organization for their active support during the year under review. Lastly I would like to extend a warm welcome to our new members of staff and record my thanks to the long-serving and loyal staff members who comprise the registry.

Dr M Z Borok Consultant Physician

MEDICAL DIRECTOR ZIMBABWE NATIONAL CANCER REGISTRY

April 2010

4

CHAIRMAN’S STATEMENT

The editors of this report are to be congratulated for producing another report in less than a year. The data for this report was collected and processed under very challenging conditions. The Registry had lost half of its staff and the difficulties faced by the healthcare delivery system in Zimbabwe during this period adversely affected operations at the Registry. We are extremely grateful to the organizations and individuals that stood by the Registry during this difficult period and I would like to add my thanks to those acknowledged in this report.

Finally, no praise could be too high for the Registry staff whose diligence, commitment and resilience have enabled us to make this important contribution to cancer control in Zimbabwe.

Mr B G Mauchaza Specialist Surgeon

CHAIRMAN ZIMBABWE CANCER REGISTRY ADVISORY COMMITTEE

April 2010

5

Figure 1: Geographical location of Zimbabwe

Cover picture: An African fish eagle (Haliaeetus vocifer) flying off with its nourishment in its right talon.

6

Figure 2: Zimbabwe Cancer Registry Advisory Committee

From left to right: Prof G Muguti, Mr S Makarawo, Prof M Chidzonga, Dr M Z Borok, Mr E Chokunonga, Mrs S Dakwa, Dr I Ticklay, Prof Z M Chirenje and Mr R Masanganise

Figure 3: Zimbabwe Cancer Registry Staff

From left to right: Mr R Mukwiza, Mrs R Rukainga, Mr E Chokunonga, Ms M Zvarevashe and Miss R D Chireshe

7

ZIMBABWE CANCER REGISTRY ADVISORY COMMITTEE Executive Committee Chairman: Mr B G Mauchaza (Specialist Surgeon)

Deputy Chairperson: Dr N Ndlovu (Consultant Radiation Oncologist)

Secretary: Dr A M Nyakabau (Consultant Radiation Oncologist)

Treasurer: Professor Z M Chirenje (Consultant Gynaecologist)

Medical Director: Dr M Z Borok (Consultant Physician) Registrar: Mr E Chokunonga (Registrar) Members Professor M Chidzonga (Dean, UZ College of Health Sciences)

Dr R Makunike-Mutasa (Consultant Pathologist)

Professor Z A R Gomo (Consultant Chemical Pathologist)

Dr M Hove (Chief Government Pathologist)

Mr R Masanganise (Consultant Opthalmologist)

Dr I Ticklay (Consultant Paediatrician)

Mr S Makarawo (Clinical Director, Parirenyatwa Group of Hospitals)

Mrs S Dakwa (Knowledge Manager, Cancer Association of Zimbabwe)

Professor G Muguti (Consultant Surgeon) STAFF: Registrar: Mr E Chokunonga Executive Assistant: Ms M Zvarevashe Data Collection Officers: Mrs R Rukainga Miss R D Chireshe Mr R Mukwiza POSTAL ADDRESS: Zimbabwe National Cancer Registry P. O. Box A449, Avondale, Harare, Zimbabwe VISITING ADDRESS: Parirenyatwa Group of Hospitals

Post Basic School of Nursing Building Mazowe Street Entrance Harare, Zimbabwe TELEPHONE: (263-4) 794445, 731000, 707707 and 730553 FAX: (263-4) 794445 EMAIL ADDRESSES: [email protected]

[email protected]

8

INTRODUCTION The Zimbabwe Cancer Registry (ZCR) is pleased to publish the Annual Report for 2006 less than a year after the release of the 2005 report in spite of the many challenges facing the registry as efforts to reduce the reporting backlog intensify. The aim of the ZCR is to reduce the reporting backlog to at least two years which is internationally acceptable. As always, the quality of data that we publish continues to take precedence over timeliness. We are also pleased to report that at the time of writing all the vacant posts at the ZCR have been filled. This development is welcome as it will have a positive impact on the performance of the Registry. Efforts are also underway to revive the Bulawayo Cancer Registry (BCR) which stopped operating because of the ongoing challenges to the healthcare delivery system in Zimbabwe. In 2006 the Registrar of the ZCR participated as member of the faculty in a regional cancer registration course organized by the IARC and the World Health Organization Regional Office for Africa (WHO/AFRO) in Johannesburg, South Africa. Mrs Rosemary Rukainga, one of the data collection officers at the ZCR, also attended the course. The Registrar also represented the organization at the 30th Annual Scientific Meeting of the International Association of Cancer Registries (IACR) that was held in Goinia, Brazil in August 2006. We are grateful to the IACR for sponsoring his participation. ACKNOWLEGEMENTS The ZCR is grateful to local and international organizations that continue to provide much needed support during these difficult economic times. The following organizations need special mention for their support during the year under review:

1. International Agency for Research on Cancer (IARC) 2. International Association of Cancer Registries (IACR) 3. World Health Organization Regional Office for Africa (WHO/AFRO) 4. World Health Organization Country Office 5. Office of International Affairs of the US National Cancer Institute 6. Medical and administrative staff of Parirenyatwa Group of Hospitals 7. Medical and administrative staff of Harare Central Hospital 8. Medical and administrative staff of the UZ College of Health Sciences 9. National Public Health Laboratories 10. Clinical Laboratories 11. CIMAS Medical Laboratories 12. Kidzcan Zimbabwe (Children’s Cancer Relief) 13. Births and Deaths Unit in the Office of the Registrar-General 14. Central Statistical Office (CSO) 15. Avenues Clinic 16. West End Hospital 17. St. Anne’s Hospital

9

Our special thanks go to the IACR, the Zimbabwe Medical Association (ZiMA) and the UZCHS for hosting our annual reports on their websites. The website addresses are: www.iacr.com.fr/zimbabwereg.htm, [email protected] and www.uz.ac.zw Lastly, we would like to thank Savanna Pharmaceuticals and the Harare Branch of the Cancer Association of Zimbabwe (CAZ) for jointly sponsoring the production of this publication. OBJECTIVES OF THE ZIMBABWE CANCER REGISTRY (ZCR) The fundamental objectives of the ZCR are:

a) To maintain a high quality population-based cancer surveillance system for Harare City that complies with the recommendations of the International Agency for Research on Cancer and the International Association of Cancer Registries.

b) To estimate the burden of the cancer problem in Zimbabwe. c) To make cancer data available for use by health educators, planners and providers

in order to plan for cancer management in a cost effective manner. d) To utilise the data available for epidemiological, clinical and other operational

research and to disseminate information on the incidence and pattern of occurrence of cancer in Zimbabwe.

e) To participate in the overall national cancer control effort by providing data on the burden of cancer in Zimbabwe.

MATERIALS AND METHODS The ZCR is a multiple source cancer registration and surveillance system that is population-based for Harare, the capital city of Zimbabwe. The registry also accepts notifications that originate from outside its target population of Harare city. The additional information is used to estimate the pattern and burden of cancer in the country. The Registry uses a combination of active and passive methods of case finding. ZCR staff visit institutions within the health-care delivery system of Harare that are involved in the diagnosis and management of cancer patients in order to register cases. Cancer notification forms are filled in for each patient. Information collected includes patient demographic data: names, date of birth/age, sex, race and usual residential address. Hospital and patient numbers, date of diagnosis, method of diagnosis, primary site, histological type, extent and stage of disease are also collected. Basic data on initial treatment and follow-up data are also collected. HIV status is also recorded when it is available. The abstract forms are matched manually and electronically with the records in the ZCR database in order to prevent multiple registrations. The main abstract form used by the ZCR is appended at the end of the report.

10

The abstract forms are coded according to the International Classification of Diseases for Oncology (ICD-O-3) and entered into the computer using the CanReg4 cancer registration software. SOURCES OF INFORMATION A number of new sources of information have been added to the list. Some sources that had been discontinued due to logistical and other reasons have been revived.

a) Public Hospitals Regular routine visits to the inpatient wards of the 2 government referral hospitals (Harare Central Hospital and Parirenyatwa Group of Hospitals) are made by ZCR staff. Patient interviews are conducted in order to record patient demographics accurately. Oncology outpatient clinics and medical records departments are also visited regularly.

b) Private Hospitals

The three major private hospitals in Harare (the St. Anne’s Hospital, the Avenues Clinic and the West End Hospital) are visited regularly to collect cancer registration forms that are filled in by hospital staff.

c) Histology Reports (public and private sectors) The National Public Health Laboratory (NPHL) is visited regularly to abstract manually the histology reports of cancer patients. The ZCR Registrar periodically visits the private Clinical Laboratories to identify and print histology reports of cancer patients from the laboratory’s electronic histology database. The CIMAS Medical Laboratory submits copies of reports to the Registry on a monthly basis.

d) Haematology Reports

The Haematology Department of the UZ College of Health Sciences provides copies of reports of haematological malignancies to the ZCR.

e) Radiology Reports

The Radiology Department at Parirenyatwa Hospital is visited regularly to review and register patients from ultrasound (USS) and CT scan reports.

f) Radiotherapy Centre

Patients managed at the Radiotherapy Centre (RTC) located at Parirenyatwa Hospital are registered through the Centre’s medical records system. ZCR staff also visit the Centre during clinic days to interview and register patients.

11

g) Death Certificates Death certificates of people who die in the greater Harare area are scrutinized weekly to record those that have died of malignant disease.

h) Clinical Case Series and Cancer Studies The ZCR makes use of records of specific cancer studies such as the ongoing Kaposi sarcoma (KS) study as well as clinical case series amassed by clinicians.

i) Bulawayo Cancer Registry (BCR)

Efforts are currently underway to reactivate the BCR. The Registry has been a major source of information for the ZCR since 1990. The BCR ceased operating in 2005 because of economic challenges.

DATA PROCESSING

a) Handling of Death Certificates Incoming death certificate abstracts are matched with records in the ZCR computer database. Information on the abstracts is used to update records of known patients. For cases that were missed but where the patients died in a medical institution, a ‘follow back’ is conducted. This involves the tracing of the patient’s records from the institution at which the patient died. A new registration is made when it is established that cancer was diagnosed. These are referred to as death certificate notifications (DCNs) since death certificates were the first source of notification. When a follow back attempt is fruitless this leads to a death certificate only (DCO) registration. In this case the death certificate is the only document available for the registration. Due to inaccuracy of death certification in some cases, DCO registrations are made after thorough vetting and consultations.

b) Registration of Skin Cancers The incidence of non-melanoma skin cancer (basal cell and squamous cell carcinomas) is quite high in the white population of Zimbabwe. This is typical of white populations of European descent living in sunny climates at low latitudes. Many patients will develop several lesions of the same histological type during their lifetime. The ZCR only records the first lesion if the histology is the same. Subsequent lesions of the same histological type are ignored. However, basal cell carcinoma and squamous cell carcinoma of the skin in the same patient affecting the same or different sites are registered separately and are regarded as multiple primary tumours.

12

c) Record Linkage and Quality Control The ZCR has over the years developed its own methods of detecting and avoiding multiple registrations to complement the conventional methods. Methods are also in place to manually and electronically identify and eliminate duplicates that would have evaded the tight record linkage process. This is essential in Africa where the use of names and other demographic data is not always consistent.

d) Classification and Coding Clinical data are coded to the third edition of the International Classification of Diseases for Oncology (ICD-O-3) and socio-demographic data are coded to a system developed by the ZCR that takes into account practices developed by the government Central Statistical Office (CSO) for national use. For data analysis purposes, data are converted to the tenth edition of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) to facilitate international comparison. Coding by Ethnic Groups Health-related data in Zimbabwe are typically collected using the colonial race classification of African, European and Coloured. We report data for the black population, meaning the population of indigenous African descent and the non-black population, which comprised the previous categories, European, Asian and Coloured.

e) Hardware

The ZCR database is computerized and the data processing hardware consists of a network of personal computers and other peripherals.

f) Software The CanReg4 cancer registration software developed by the International Agency for Research on Cancer is used for data processing. It is a reliable system that currently adequately meets the data processing requirements of the ZCR.

USE OF DATA FROM THE CANCER REGISTRY The existence of a cancer registry is usually justified by the extent to which the database is used for research and other purposes. In this regard, the ZCR encourages the use of its data by organizations and individuals in accordance with the legal requirements relating to patient medical information. The recommendations of the IACR/IARC regarding confidentiality for population-based cancer registries are strictly observed.

13

The ZCR is pleased with the current level of use of its database evidenced by increased requests for data. The data are extensively utilized by indigenous and international researchers, conference participants, lecturers, students, health educators and policy makers for management planning and cancer control programmes. In recent times, the ZCR has become increasingly involved in national cancer control issues. It is represented on the Prevention of Cancer Committee for Zimbabwe (PCCZ). It is also part of the Zimbabwe HPV vaccine Advocacy Group which is advocating for the introduction of the HPV Vaccine in Zimbabwe. We are pleased with this development because a cancer registry is an essential part of any rational programme of national cancer control. RESULTS In this report, we present an analysis of new cases of cancer among Zimbabweans diagnosed in 2006. The analysis excludes non-Zimbabweans referred from neighboring countries for management in Zimbabwe and patients that were diagnosed in previous years but were registered in 2006. Benign and uncertain tumours (including in-situ tumours and CIN III lesions) are also excluded in the analysis. The results are presented in tabular form as percentage frequencies using the standard ICD-10 format. Graphs are used to depict the predominant tumours and other relevant observations by gender and ethnic groups, both of which have a bearing on cancer risk. The total number of new cases of cancer recorded among Zimbabweans in 2006 was 4 175 comprising 1 842 (44.1%) males and 2 333 (55.9%) females. In Harare City (target population of the registry) a total of 1 922 malignant tumours consisting of 900 (46.8%) males and 1 022 (53.2%) females were registered in 2006. The leading cause of cancer among Zimbabwean black men in 2006 was Kaposi sarcoma (KS) (23.8%). This was followed by prostate (13.1%), eye (6.5%), non-Hodgkin lymphoma (NHL) (6.2%), oesophagus (6.2%), liver (4.9%), stomach (3.8%), lung (3.0%), bladder (2.9%) and non-melanoma of skin cancer (2.7%). In Zimbabwean black women the most frequent cancers were cervical cancer (32.5%), KS (11.9%), breast (11.7%), eye (4.4%), NHL (4.2%), ovary (3.5%), non-melanoma of skin cancer (2.9%), stomach (2.3%), oesophagus (2.3%) and liver (2.2%). Non-melanoma of skin cancer was the commonest cancer among Zimbabwean non-black men (56.7%). This was followed by prostate (12.1%), colon (4.9%), rectum (2.6%), melanoma of skin cancer (2.6%), bladder (2.6%), lung (1.6%), brain and nervous system (1.6%), NHL (1.6%) and oesophagus (1.3%). The leading cancers in non-black Zimbabwean women were non-melanoma of skin cancer (44.6%), breast (23.8%), colon (4.3%), ovary (2.2%), corpus uteri (2.2%), NHL (2.2%), melanoma of skin (1.7%), oesophagus (1.7%), bladder (1.7%) and lung (1.3%).

14

A total number of 151 childhood cancers (age 0-14) comprising 89 boys (58.9%) and 62 girls (41.1%) were recorded among Zimbabweans of all races in 2006. Childhood cancer represented 3.6% of the cancers registered in 2006. The most frequent cancers in boys were retinoblastoma (18.0%), Wilms tumour (16.9%), NHL (16.9%), KS (12.4%), leukaemia (10.1%), brain and nervous system (7.9%), Hodgkin disease (HD) (4.5%), bone (3.4%), connective and soft tissue (2.4%) and non-melanoma of skin cancer (2.2%). The most common cancer in girls was Wilms tumour (14.5%). This was followed by KS (12.9%), retinoblastoma (12.9%), leukaemia (11.3%), NHL (8.1%), bone (8.1%), ovary (6.5%), connective and soft tissue (6.5%), brain and nervous system (4.8%) and HD (3.2%). The leading cancers in Harare black men in 2006 were KS (21.8%), prostate (16.7%), liver (8.0%), oesophagus (6.4%), NHL (5.8%), lung (4.4%), stomach (4.1%), bladder (3.3%), eye (2.9%) and colon (2.8%). Cervical cancer predominated in the black female population of Harare (28.7%). This was followed by KS (13.4%), breast (11.9%), ovary (4.6%), NHL (4.2%), oesophagus (3.4%), stomach (3.4%), liver (2.8%), bladder (2.4%) and corpus uteri (2.4%). The most common cancers in Harare non-black men in 2006 were non-melanoma of skin cancer (44.9%), prostate (16.5%), colon (5.1%), rectum (4.0%), melanoma of skin cancer (4.0%), NHL (2.8%), oesophagus (2.3%), bladder (2.3%), lung (2.3%) and brain and nervous system (1.7%). In Harare non-black women the commonest cancers were non-melanoma of skin cancer (39.6%), breast (23.0%), colon (5.0%), NHL (3.6%), bladder (2.9%), corpus uteri (2.9%), melanoma of skin cancer (2.2%), pancreas (2.2%), mouth (2.2%) and lung (1.4%). For the first time, we present basic mortality data based on cancer deaths that occurred in Harare City in year 2006. Although the data is not representative for the whole country it gives an important insight into the causes of cancer deaths in Zimbabwe. A total of 1 164 cancer deaths were recorded in Harare in 2006. Of the reported cases, the leading causes of the deaths were KS (15%), cancer of the cervix (10%), breast cancer (8%), primary liver cancer (8%), oesophagus (6%), NHL (6%), prostate (6%), lung (4%) and stomach (4%). Other cancer sites constituted 33% of the recorded deaths. Tables 1 and 2 show the sources of information of cancers recorded in 2006 and the methods by which the cancers were diagnosed for both Harare City and Zimbabwe. Figures 4-5 show the age distribution of cervical cancer and breast cancer. The age distribution of KS and prostate cancer is depicted in figures 6-7. Figures 8-9 show the age distribution of NHL and eye cancers. Figures 10-11 show percentage frequencies of incident cases and cancer deaths recorded in 2006.

15

Figures 12-23 show the percentage frequencies of the top ten cancers recorded in Harare and Zimbabwe by gender and ethnic groups. Figures 24-25 show the most common childhood cancers by gender. Tables 3-14 show the age, sex and site distribution of all the cancers recorded in Harare and Zimbabwe by ethnic groups. DISCUSSION The last three years (2007-2009) were very difficult socially, politically and economically for Zimbabwe. The severe economic challenges experienced in the country adversely affected the healthcare delivery system leading to the near collapse of public sector component in 2008. Most departments of government central referral hospitals operated below capacity and some of them closed altogether. The Zimbabwe Cancer Registry (ZCR) which mainly relies on public sector institutions for its data was not spared of the challenges faced by the system during the period. The ZCR lost some of its experienced staff. It is important to note that it was during this period of great difficulty and uncertainty that the data for this report for 2006 was collected and processed. We are pleased that the ZCR managed to survive this turbulent phase representing the most difficult time since the inception of the ZCR in 1985. 2009 closed on a highly optimistic note. The staffing situation was resolved and we are grateful to the Ministry of Health and Child Welfare for this. The period from September 2009 to March 2010 was very busy for the ZCR. It involved the training of new staff and clearing of data collection backlog that had accrued at most of the sources of information. Tremendous effort was invested in backtracking and revisiting data sources in order to ensure complete case ascertainment and coverage of our target population of Harare urban. We are pleased to note that this has been achieved and this effort has culminated in the production and publication of this report. Although the national number of new cases of cancer registered in 2006 declined significantly largely because of the closure of the Bulawayo Cancer Registry (BCR) it is important to note that the incident cases for Harare (target population of the registry) remained stable. The pattern of occurrence of cancer did not change for both Harare and Zimbabwe. The false decline of new cases nationally is expected to continue in the next two reports of the ZCR until the healthcare system becomes fully functional. From the ZCR point of view, revival of the BCR is fundamental to improvement of national reporting and coverage and efforts will be directed to achieving this in the upcoming months.

16

The evolving epidemic of HIV/AIDS in Zimbabwe continues to have a major influence on the incidence and pattern of occurrence of cancer in the country. The most frequently occurring cancers in Zimbabwe that are associated with HIV/AIDS are Kaposi sarcoma (KS), squamous cell carcinoma of the conjunctiva and non-Hodgkin lymphoma. This is consistent with observations made in other sub-Saharan countries of Africa. Finally, we would once again like to thank all the individuals and organizations that continue to stand by the Zimbabwe Cancer Registry during this difficult period.

Mr E Chokunonga REGISTRAR

ZIMBABWE NATIONAL CANCER REGISTRY April 2010

17

REFERENCES 1. Cancer Registration Principles and Methods. Editors: O.M. Jensen, D.M.

Parkin, R. Maclennan, C.S. Muir and R.G. Skeet. IARC Scientific Publication No. 95, Lyon, (1991).

2. Guidelines on Confidentiality for Population-based Cancer Registration.

IARC Internal Report No. 2004/03 (2004).

3. International Rules for Multiple Primary Cancers (ICD-O Third Edition), Lyon, 2004.

4. Chokunonga, E., Zimbabwe National Cancer Registry Code Book. 2nd edition

(2004). 5. World Health Organisation, International Statistical Classification of Diseases

and Related Health Problems. 10th edition, WHO, Geneva, 1992.

6. Fritz, A., Percy, C. Jack, A., Shanmugaratnam, K., Parkin, D.M. and Whelan, S. (Eds). International Classification of Diseases for Oncology, 3rd edition. World Health Organisation, Geneva, (2000).

7. CanReg4 Manual. Contributors: M.P. Curado, Morten Ervik, H.R. Shin, J.

Ferlay, Seon Hee Yim, Hyun Joo Kong, Max Parkin, Paola Pisani, Krittika Pitaksaringkam and Sophie Dhal.

8. E. Chokunonga, M.Z. Borok, B.G. Mauchaza, Z.M. Chirenje and A.M.

Nyakabau. In: Curado. M.P., Edwards, B., Shin. H.R., Storm. H., Ferlay. J., Heanue. M and Boyle. P., Eds. (2007) Cancer Incidence in Five Continents, Vol. IX, IARC Scientific Publications No. 160, Lyon, IARC.

9. National Cancer Control Programme for Zimbabwe: Ten Year Plan 1994-2004. Prevention of Cancer Committee for Zimbabwe (PCCZ). (1998)

18

ACRONYMS BCR Bulawayo Cancer Registry CanReg Cancer Registration Computer Software CAZ Cancer Association of Zimbabwe CSO Central Statistical Office DCN Death Certificate Notification DCO Death Certificate Only HD Hodgkin disease IACR International Association of Cancer Registries IARC International Agency for Research on Cancer ICD-10 International Classification of Diseases – 10th revision edition ICD-O-3 International Classification of Diseases for Oncology, 3rd Edition KS Kaposi sarcoma MoHCW Ministry of Health and Child Welfare NCI National Cancer Institute NHL Non-Hodgkin lymphoma PCCZ Prevention of Cancer Committee for Zimbabwe RTC Radiotherapy Centre UZCHS University of Zimbabwe College of Health Sciences UZ University of Zimbabwe WHO World Health Organization ZCR Zimbabwe Cancer Registry

19

ZCR PUBLICATIONS

1. Bassett, M.T., Levy L.M., Chetsanga, C.J. and Chokunonga, E., Zimbabwe National Cancer Registry Summary Data 1986-1989. Centr. Afr. J. Medicine. 38, 91-94 (1992).

2. Bassett, M.T., Chokunonga, E., Levy, L., Mauchaza, B.G., Ferlay, J. and Parkin,

D.M., Cancer in the African Population of Harare, Zimbabwe, 1990-1992. Int. J. Cancer, 63, 29-36 (1995).

3. Bassett, M.T., Levy, L., Chokunonga, E., Mauchaza, B., Ferlay, J. and Parkin,

D.M., Cancer in the European Population of Harare, Zimbabwe, 1990-1992. Int. J. Cancer, 63, 24-28 (1995).

4. Bassett, M.T., Chokunonga, E., Levy, L. and Mauchaza, B., in Cancer Incidence

in Five Continents Vol. VII, eds. D.M. Parkin, S.L. Whelan, J. Ferlay, L. Raymond and J. Young. IARC Scientific Publication No. 143, Lyon, 1997.

5. Watts, T., Siziya, S. and Chokunonga, E., Cancer of the Skin in Zimbabwe: an

analysis based on the Cancer Registry 1986 to 1992. Centr. Afr. J. Medicine. 43, (7): 181-4 (1997).

6. Chokunonga, E., Bassett, M.T., Levy, L.M., Mauchaza, B.G., Abayomi, A. and

Chitsike, I., in International Incidence of Childhood Cancer Vol. II, eds. Parkin, D.M., Kramarova, E., Draper, G.J. IARC Scientific Publication No. 144, Lyon, 1998.

7. Chokunonga, E., Levy, L.M., Bassett, M.T., Borok, M.Z., Mauchaza, B.G.,

Chirenje, Z.M. and Parkin, D.M., Aids and Cancer in Africa: The Evolving Epidemic in Zimbabwe. AIDS, 13, 2583-2588 (1999).

8. Chokunonga, E., Levy, L.M., Bassett, M.T., Mauchaza, B.G., Thomas, D.B., and

Parkin, D.M. Cancer Incidence in the African Population of Harare, Zimbabwe: Second Results from the Cancer Registry 1993-1995. Int. J. Cancer. 85, 54-59 (2000).

9. Chokunonga, E., Levy, L.M., Bassett, M.T. and Mauchaza, B.G., in Cancer

Incidence in Five continents Vol. VIII, eds. D.M. Parkin, S.L. Whelan, J. Ferlay, L. Teppo and D.B. Thomas. IARC Scientific Publication No. 155, Lyon, 2002.

10. Bassett, M.T. and Chokunonga, E. in Cancer in Africa, Epidemiology and

Prevention. Eds. D.M. Parkin, J. Ferlay, M. Hamdi-Cherif, F. Sitas, J. Thomas, H. Wabinga and S. Whelan. IARC Scientific Publication No. 153, Lyon.

20

11. Chokunonga, E., Ramanakumar, A.V., Nyakabau, A.M., Borok, M.Z., Chirenje, Z.M., Sankila, R. and Parkin, D.M. Survival of cervix cancer patients in Harare, Zimbabwe, 1995-1997. Int. J. Cancer, 109, 274-277 (2004).

12. Adam Gondos, Eric Chokunonga, Hermann Brenner, Donald Maxwell Parkin,

Risto Sankila, Margaret Borok, Z. Michael Chirenje, Anna M. Nyakabau and Mary Travis Bassett, Cancer Survival in a Southern African Urban Population. Int. J. Cancer, 112, 860-864 (2004).

13. A. Gondos, D.M. Parkin, E. Chokunonga and H. Brenner. Calculating age-

adjusted cancer survival estimates when age-specific data are sparse: an empirical evaluation of various methods. Br. J. Cancer 94, 450-454 (2006).

14. E. Chokunonga, M.Z. Borok, B.G. Mauchaza, Z.M. Chirenje and A.M.

Nyakabau. In: Curado. M.P., Edwards, B., Shin. H.R., Storm. H., Ferlay. J., Heanue. M and Boyle. P., Eds. (2007) Cancer Incidence in Five Continents, Vol. IX, IARC Scientific Publications No. 160, Lyon, IARC.

15. Chokunonga, E. et al, Pattern of Cancer in Zimbabwe: Zimbabwe National

Cancer Registry Annual Reports. (1990-2006).

21

Table 1

SOURCE OF INFORMATION OF CANCERS REGISTERED IN 2006

HARARE CITY

ZIMBABWE

SOURCE OF INFORMATION CASES

% CASES

%

Patient Interviews Hospital Medical Records Histology Reports Death Certificates Bulawayo Cancer Registry Other

484454662281 -41

25.223.634.414.6

-2.2

793 775

2185 329 56 37

19.018.652.3 7.91.30.9

TOTAL 1 922 100.0 4 175 100.0 Source of information refers to the first source of notification of the cancer case.

Table 2 METHOD OF DIAGNOSIS OF CANCERS REGISTERED IN 2006

HARARE CITY

ZIMBABWE

METHOD OF DIAGNOSIS

CASES % CASES

%

Death Certificate Only (DCO) Clinical* Histology** Other

244544

1 134-

12.728.359.0

-

284 805

3 086 -

6.819.373.9

-

TOTAL 1 922 100.0 4 175 100.0 *Clinical: clinical only, x-rays, scans, surgery etc. **Histology: histology of primary site and metastasis, haematology and cytology.

22

Figure 4

INCIDENCE: 2006

16%

15%

9%

7%6% 5%

5%

3%

3%

31%

CERVIXKSNMSBREASTPROSTATEEYENHLLIVERSTOMACHOTHER

Figure 5

MORTALITY: 2006

15%

10%

8%

8%

6%6% 6% 4%

4%

33%

KSCERVIXBREASTLIVEROESOPHAGUSNHLPROSTATELUNGSTOMACHOTHER

KS = Kaposi sarcoma NHL = Non-Hodgkin lymphoma NMS = Non-melanoma of skin

23

Figure 6

CERVICAL CANCER 2006: Age Distribution: Zimbabwe

0

20

40

60

80

100

120

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+

AGE GROUP

CAS

ES

Figure 7 BREAST CANCER

2006: Age Distribution: Zimbabwe

0

10

20

30

40

50

60

70

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+

AGE GROUP

CAS

ES

24

Figure 8

KAPOSI SARCOMA


0

10

20

30

40

50

60

70

80

90

100

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-69 60-64 65+

AGE GROUP

CA

SES

male female

Figure 9 PROSTATE CANCER


0

20

40

60

80

100

120

140

160

180

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65+

AGE GROUP

CA

SES

25

Figure 10 NON-HODGKIN LYMPHOMA


0

2

4

6

8

10

12

14

16

18

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-69 60-64 65+

AGE GROUP

CA

SES

male female

Figure 11 EYE CANCERS


0

5

10

15

20

25

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-69 60-64 65+

AGE GROUP

CA

SES

male female

26

Figure 12 MOST COMMON CANCERS

2006: Zimbabwean Blacks: Males

2.7

2.9

3

3.8

4.9

6.2

6.2

6.5

13.1

23.8

0 5 10 15 20 25

NON-MELANOMA OF SKIN

BLADDER

LUNG

STOMACH

LIVER

OESOPHAGUS

NON-HODGKIN LYMPHOMA

EYE

PROSTATE

KAPOSI SARCOMA

SITE

PERCENTAGE

Figure 13

2006: Zimbabwean Blacks: Females

2.2

2.3

2.3

2.9

3.5

4.2

4.4

11.7

11.9

32.5

0 5 10 15 20 25 30 35

LIVER

OESOPHAGUS

STOMACH


OVARY


EYE

BREAST

KAPOSI SARCOMA

CERVIX UTERI

SITE

PERCENTAGE

27

TABLE 3 AGE, SEX AND SITE DISTRIBUTION: 2006 MALE: ZIMBABWEAN BLACKS

NUMBER OF CASES BY AGE GROOUP ================================================================================================================================== SITE All Age 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65+ % of ICD Ages Unk. - 4 - 9 -14 -19 -24 -29 -34 -39 -44 -49 -54 -59 -64 Total (10th) ================================================================================================================================== Lip 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C00 Tongue 2 : 0 : 0 0 0 0 0 0 0 0 0 0 1 0 0 1 : 0.1% : C01-C02 Mouth 8 : 0 : 0 0 0 1 0 1 0 0 1 3 0 1 0 1 : 0.5% : C03-C06 Salivary glands 7 : 2 : 0 1 0 0 0 1 0 0 0 2 0 1 0 0 : 0.5% : C07-C08 Tonsil 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C09 Other Oropharynx 1 : 0 : 0 0 0 0 0 0 1 0 0 0 0 0 0 0 : 0.1% : C10 Nasopharynx 7 : 1 : 0 0 0 1 0 0 0 0 0 1 0 1 0 3 : 0.5% : C11 Hypopharynx 1 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 1 : 0.1% : C12-C13 Pharynx unspec. 5 : 1 : 0 0 0 0 0 0 0 0 1 0 1 0 1 1 : 0.3% : C14 Oesophagus 96 : 0 : 0 0 0 0 1 1 4 7 4 11 7 11 5 45 : 6.2% : C15 Stomach 58 : 0 : 0 0 0 0 0 1 1 2 3 4 4 8 2 33 : 3.8% : C16 Small intestine 4 : 0 : 0 0 0 0 0 0 0 0 0 0 0 2 2 0 : 0.3% : C17 Colon 37 : 1 : 0 0 0 0 1 0 0 3 2 5 4 4 4 13 : 2.4% : C18 Rectum 36 : 1 : 0 0 0 1 3 3 6 0 4 0 2 1 8 7 : 2.3% : C19-C20 Anus 3 : 0 : 0 0 0 0 0 0 2 1 0 0 0 0 0 0 : 0.2% : C21 Liver 76 : 0 : 0 0 1 1 2 6 5 4 8 5 9 5 8 22 : 4.9% : C22 Gallbladder etc. 6 : 0 : 0 0 0 0 0 0 0 1 1 1 0 0 1 2 : 0.4% : C23-C24 Pancreas 18 : 0 : 0 0 0 0 0 0 0 0 0 2 1 2 3 10 : 1.2% : C25 Nose, sinuses etc. 13 : 1 : 0 0 0 0 0 2 0 2 0 2 0 1 2 3 : 0.8% : C30-C31 Larynx 29 : 1 : 0 0 0 0 0 0 0 0 1 6 2 5 1 13 : 1.9% : C32 Trachea,Bronchus,Lung 46 : 0 : 0 0 0 0 0 1 2 1 6 1 2 11 2 20 : 3.0% : C33-C34 Other Thoracic organs 3 : 0 : 0 0 0 0 1 0 0 0 0 1 0 0 0 1 : 0.2% : C37-C38 Bone 38 : 0 : 0 1 2 10 6 4 3 2 3 1 2 0 1 3 : 2.5% : C40-C41 Melanoma of Skin 18 : 1 : 0 1 0 1 0 0 2 1 1 0 1 0 3 7 : 1.2% : C43 Other Skin 41 : 4 : 1 0 0 0 1 2 2 2 10 6 3 1 2 7 : 2.7% : C44 Mesothelioma 1 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 1 : 0.1% : C45 Kaposi sarcoma 366 : 29 : 4 2 5 2 7 25 85 66 41 32 22 15 12 19 : 23.8% : C46 Connective,Soft tissue 22 : 0 : 0 0 2 3 4 3 2 2 1 0 1 0 1 3 : 1.4% : C47;C49 Breast 10 : 0 : 0 0 0 0 0 0 2 1 1 0 0 1 3 2 : 0.7% : C50 Penis 8 : 1 : 0 0 0 0 0 0 0 1 0 0 1 2 0 3 : 0.5% : C60 Prostate 201 : 6 : 0 0 0 0 0 0 1 1 1 4 7 12 25 144 : 13.1% : C61 Testis 2 : 0 : 0 0 0 0 0 0 0 1 1 0 0 0 0 0 : 0.1% : C62 Other male genital 2 : 0 : 0 0 0 0 0 1 0 1 0 0 0 0 0 0 : 0.1% : C63 Kidney 25 : 0 : 13 1 1 0 0 0 1 0 1 1 2 3 1 1 : 1.6% : C64 Renal Pelvis 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C65 Ureter 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C66 Bladder 44 : 0 : 1 0 0 0 0 1 2 1 1 2 3 2 9 22 : 2.9% : C67 Other Urinary organs 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C68 Eye 100 : 9 : 14 2 0 0 0 2 12 21 19 5 8 2 1 5 : 6.5% : C69 Brain, Nervous system 19 : 0 : 3 2 2 4 0 3 1 0 0 0 2 0 0 2 : 1.2% : C70-C72 Thyroid 7 : 0 : 0 0 0 0 0 0 1 0 0 2 0 0 2 2 : 0.5% : C73 Adrenal gland 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C74 Other Endocrine 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C75 Hodgkin disease 6 : 0 : 0 1 3 1 0 0 0 0 0 0 0 0 0 1 : 0.4% : C81 Non-Hodgkin lymphoma 95 : 4 : 5 6 4 1 2 4 11 16 12 8 11 2 4 5 : 6.2% : C82-Immunoproliferative dis. 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C88

C85

Multiple Myeloma 8 : 0 : 0 0 0 0 0 0 1 0 2 0 2 0 0 3 : 0.5% : C90 Lymphoid Leukaemia 8 : 1 : 1 1 1 0 0 0 0 0 0 1 0 0 3 0 : 0.5% : C91 Myeloid Leukaemia 11 : 0 : 2 0 0 0 1 3 0 2 1 2 0 0 0 0 : 0.7% : C92-C94 Leukaemia unspec. 7 : 0 : 0 1 3 0 0 0 0 1 0 0 0 0 0 2 : 0.5% : C95 Other & unspecified 42 : 3 : 0 0 1 0 1 2 3 3 5 3 5 3 4 9 : 2.7% : ==================================================================================================================================

Other

A LL SITES 1537 : 66 : 44 19 25 26 30 66 150 143 131 111 103 96 110 417 :100.0% :

==================================================================================================================================

28

TABLE 4 AGE, SEX AND SITE DISTRIBUTION: 2006 FEMALE: ZIMBABWEAN BLACKS

NUMBER OF CASES BY AGE GROUP ================================================================================================================================== SITE All Age 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65+ % of ICD Ages Unk. - 4 - 9 -14 -19 -24 -29 -34 -39 -44 -49 -54 -59 -64 Total (10th) ================================================================================================================================== Lip 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C00 Tongue 2 : 1 : 0 0 0 0 0 0 0 0 0 0 0 1 0 0 : 0.1% : C01-C02 Mouth 6 : 3 : 0 0 0 0 0 0 0 0 0 0 0 1 0 2 : 0.3% : C03-C06 Salivary glands 4 : 0 : 0 0 0 0 0 0 1 0 1 0 1 0 0 1 : 0.2% : C07-C08 Tonsil 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C09 Other Oropharynx 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C10 Nasopharynx 4 : 0 : 0 0 1 1 0 0 1 0 0 0 0 1 0 0 : 0.2% : C11 Hypopharynx 1 : 0 : 0 0 0 0 0 0 0 0 0 0 0 1 0 0 : 0.0% : C12-C13 Pharynx unspec. 1 : 0 : 0 0 0 0 0 0 0 0 0 0 0 1 0 0 : 0.0% : C14 Oesophagus 48 : 2 : 0 0 0 0 0 0 2 2 3 1 5 6 5 22 : 2.3% : C15 Stomach 48 : 1 : 0 0 0 0 1 0 0 2 4 2 2 11 7 18 : 2.3% : C16 Small intestine 1 : 0 : 0 0 0 0 0 0 0 0 0 0 0 1 0 0 : 0.0% : C17 Colon 30 : 2 : 0 0 0 0 2 0 0 1 4 3 4 4 2 8 : 1.4% : C18 Rectum 33 : 0 : 0 0 0 1 0 3 1 3 2 10 3 2 0 8 : 1.6% : C19-C20 Anus 7 : 0 : 0 0 0 0 0 0 3 1 0 0 1 0 0 2 : 0.3% : C21 Liver 46 : 2 : 1 0 0 0 2 2 1 1 4 2 1 3 1 26 : 2.2% : C22 Gallbladder etc. 5 : 0 : 0 0 0 0 0 0 1 0 0 0 0 2 0 2 : 0.2% : C23-C24 Pancreas 17 : 0 : 0 0 0 0 0 0 0 0 0 0 4 4 2 7 : 0.8% : C25 Nose, sinuses etc. 11 : 1 : 0 0 1 0 1 1 1 0 2 2 0 0 1 1 : 0.5% : C30-C31 Larynx 5 : 0 : 0 0 0 0 0 0 0 1 2 0 0 0 0 2 : 0.2% : C32 Trachea,Bronchus,Lung 20 : 1 : 0 0 0 0 0 1 2 3 0 2 1 1 3 6 : 1.0% : C33-C34 Other Thoracic organs 1 : 1 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C37-C38 Bone 24 : 2 : 0 3 2 3 4 5 1 3 1 0 0 0 0 0 : 1.1% : C40-C41 Melanoma of Skin 15 : 2 : 0 0 0 0 1 0 0 0 1 1 0 2 1 7 : 0.7% : C43 Other Skin 60 : 11 : 0 0 0 1 4 2 3 4 4 1 9 3 4 14 : 2.9% : C44 Mesothelioma 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C45 Kaposi sarcoma 251 : 21 : 2 2 4 2 10 39 60 41 23 17 14 9 2 5 : 11.9% : C46 Connective,Soft tissue 20 : 1 : 2 0 2 0 3 0 4 1 0 1 2 1 2 1 : 1.0% : C47;C49 Breast 245 : 12 : 0 0 0 3 5 13 14 34 28 30 33 21 19 33 : 11.7% : C50 Vulva 14 : 0 : 0 0 0 0 0 2 1 2 0 1 3 2 2 1 : 0.7% : C51 Vagina 10 : 1 : 0 0 1 0 0 1 2 0 2 0 0 0 1 2 : 0.5% : C52 Cervix Uteri 683 : 62 : 0 0 0 0 3 15 61 65 72 93 80 64 61 107 : 32.5% : C53 Corpus Uteri 44 : 3 : 0 0 0 0 1 2 1 0 3 5 1 3 8 17 : 2.1% : C54 Uterus unspec. 14 : 0 : 0 0 0 0 0 0 0 1 0 2 1 2 4 4 : 0.7% : C55 Ovary 74 : 2 : 0 1 3 1 5 5 10 7 8 6 9 4 3 10 : 3.5% : C56 Other Female Genital 1 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 1 0 : 0.0% : C57 Placenta 17 : 1 : 0 0 0 0 5 2 2 1 1 1 3 1 0 0 : 0.8% : C58 Kidney 14 : 1 : 6 0 3 0 0 0 0 0 0 0 1 0 3 0 : 0.7% : C64 Renal Pelvis 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C65 Ureter 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C66 Bladder 32 : 1 : 0 0 0 1 0 0 0 3 2 4 4 3 1 13 : 1.5% : C67 Other Urinary organs 1 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 1 : 0.0% : C68 Eye 92 : 16 : 6 1 1 1 5 12 19 8 11 5 2 0 3 2 : 4.4% : C69 Brain, Nervous system 12 : 0 : 1 1 1 1 0 2 0 0 1 2 0 1 1 1 : 0.6% : C70-C72 Thyroid 22 : 0 : 0 0 0 0 0 1 2 3 2 2 2 4 1 5 : 1.0% : C73 Adrenal gland 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C74 Other Endocrine 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C75 Hodgkin disease 7 : 1 : 0 0 2 1 0 0 1 0 1 0 1 0 0 0 : 0.3% : C81 Non-Hodgkin lymphoma 89 : 9 : 0 2 3 2 1 9 12 13 9 8 8 6 3 4 : 4.2% : C82-C85 Immunoproliferative dis. 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C88 Multiple Myeloma 8 : 0 : 0 0 0 0 0 0 0 0 0 1 1 3 0 3 : 0.4% : C90 Lymphoid Leukaemia 11 : 0 : 0 4 2 0 1 0 0 0 0 0 0 3 1 0 : 0.5% : C91 Myeloid Leukaemia 5 : 1 : 0 1 0 1 0 0 1 0 0 0 0 0 0 1 : 0.2% : C92-C94 Leukaemia unspec. 1 : 0 : 0 0 0 0 0 0 0 0 1 0 0 0 0 0 : 0.0% : C95 Other & unspecified 46 : 2 : 2 1 0 2 3 0 2 0 1 3 2 4 9 15 : 2.2% : Other ================================================================================================================================== ALL SITES 2102 :163 : 20 16 26 21 57 117 209 200 193 205 198 175 151 351 :100.0% : ==================================================================================================================================

29


2006: Zimbabwean Non-Blacks: Males

1.3

1.6

1.6

1.6

2.6

2.6

2.6

4.9

12.1

56.7

0 10 20 30 40 50 60

OESOPHAGUS


BRAIN, NERVOUS SYSTEM

LUNG

BLADDER

MELANOMA OF SKIN

RECTUM

COLON

PROSTATE


SITE

PERCENTAGE

Figure 15

2006: Zimbabwean Non-Blacks: Females

1.3

1.7

1.7

1.7

2.2

2.2

2.2

4.3

23.8

44.6

0 10 20 30 40 5

LUNG

BLADDER

OESOPHAGUS

MELANOMA OF SKIN


CORPUS UTERI

OVARY

COLON

BREAST


SITE

PERCENTAGE 0

30

TABLE 5 AGE, SEX AND SITE DISTRIBUTION: 2006 MALE: ZIMBAWEAN NON-BLACKS

NUMBER OF CASES BY AGE GROUP ================================================================================================================================== SITE All Age 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65+ % of ICD Ages Unk. - 4 - 9 -14 -19 -24 -29 -34 -39 -44 -49 -54 -59 -64 Total (10th) ================================================================================================================================== Lip 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C00 Tongue 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C01-C02 Mouth 1 : 0 : 0 0 0 0 0 0 0 0 0 0 0 1 0 0 : 0.3% : C03-C06 Salivary glands 1 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 1 : 0.3% : C07-C08 Tonsil 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C09 Other Oropharynx 1 : 0 : 0 0 0 0 0 0 0 0 0 0 0 1 0 0 : 0.3% : C10 Nasopharynx 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C11 Hypopharynx 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C12-C13 Pharynx unspec. 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C14 Oesophagus 4 : 0 : 0 0 0 0 0 0 0 0 0 0 0 1 1 2 : 1.3% : C15 Stomach 2 : 1 : 0 0 0 0 0 0 0 0 0 0 1 0 0 0 : 0.7% : C16 Small intestine 1 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 1 : 0.3% : C17 Colon 15 : 0 : 0 0 0 0 0 0 0 0 0 0 0 2 1 12 : 4.9% : C18 Rectum 8 : 0 : 0 0 0 0 0 0 0 0 0 0 1 0 3 4 : 2.6% : C19-C20 Anus 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C21 Liver 2 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 2 : 0.7% : C22 Gallbladder etc. 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C23-C24 Pancreas 2 : 0 : 0 0 0 0 0 0 0 0 0 1 0 0 1 0 : 0.7% : C25 Nose, sinuses etc. 1 : 0 : 0 0 0 0 0 0 0 0 0 0 1 0 0 0 : 0.3% : C30-C31 Larynx 1 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 1 0 : 0.3% : C32 Trachea,Bronchus,Lung 5 : 0 : 0 0 0 0 0 0 0 0 0 1 1 0 1 2 : 1.6% : C33-C34 Other Thoracic organs 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C37-C38 Bone 1 : 0 : 0 0 0 0 0 1 0 0 0 0 0 0 0 0 : 0.3% : C40-C41 Melanoma of Skin 8 : 0 : 0 0 0 0 0 0 0 0 0 2 2 0 1 3 : 2.6% : C43 Other Skin 173 : 5 : 0 0 1 0 1 3 2 5 4 13 13 17 25 84 : 56.7% : C44 Mesothelioma 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C45 Kaposi sarcoma 1 : 0 : 0 0 0 0 0 0 1 0 0 0 0 0 0 0 : 0.3% : C46 Connective,Soft tissue 2 : 0 : 0 0 0 0 0 0 0 0 0 0 0 1 0 1 : 0.7% : C47;C49 Breast 1 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 1 : 0.3% : C50 Penis 1 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 1 : 0.3% : C60 Prostate 37 : 0 : 0 0 0 0 0 0 0 0 0 1 1 2 2 31 : 12.1% : C61 Testis 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C62 Other male genital 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C63 Kidney 4 : 0 : 0 0 0 0 0 0 0 0 0 1 0 1 1 1 : 1.3% : C64 Renal Pelvis 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C65 Ureter 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C66 Bladder 8 : 1 : 0 0 0 0 0 0 0 0 0 0 0 0 1 6 : 2.6% : C67 Other Urinary organs 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C68 Eye 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C69 Brain, Nervous system 5 : 0 : 0 0 0 0 0 0 0 0 0 0 1 0 1 3 : 1.6% : C70-C72 Thyroid 2 : 0 : 0 0 0 0 0 0 0 0 0 0 1 0 0 1 : 0.7% : C73 Adrenal gland 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C74 Other Endocrine 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C75 Hodgkin disease 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C81 Non-Hodgkin lymphoma 5 : 0 : 0 0 0 0 1 0 0 0 0 1 1 0 0 2 : 1.6% : C82-Immunoproliferative dis. 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C88

C85


Other

A LL SITES 305 : 7 : 0 0 1 0 2 4 3 5 4 22 23 27 39 168 :100.0% :

==================================================================================================================================

31

TABLE 6 AGE, SEX AND SITE DISTRIBUTION: 2006 FEMALE: ZIMBABWEAN NON-BLACKS

NUMBER OF CASES BY AGE GROUP ================================================================================================================================== SITE All Age 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65+ % of ICD Ages Unk. - 4 - 9 -14 -19 -24 -29 -34 -39 -44 -49 -54 -59 -64 Total (10th) ================================================================================================================================== Lip 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C00 Tongue 3 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 3 : 1.3% : C01-C02 Mouth 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C03-C06 Salivary glands 1 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 1 : 0.4% : C07-Tonsil 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C09

C08

Other Oropharynx 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C10 Nasopharynx 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C11 Hypopharynx 2 : 0 : 0 0 0 0 0 0 0 0 0 0 0 1 0 1 : 0.9% : C12-C13 Pharynx unspec. 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C14 Oesophagus 4 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 2 2 : 1.7% : C15 Stomach 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C16 Small intestine 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C17 Colon 10 : 1 : 0 0 0 0 0 0 0 0 0 0 1 1 1 6 : 4.3% : C18 Rectum 1 : 0 : 0 0 0 0 0 0 0 0 0 0 1 0 0 0 : 0.4% : C19-C20 Anus 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C21 Liver 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C22 Gallbladder etc. 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C23-C24 Pancreas 3 : 0 : 0 0 0 0 0 0 1 0 0 0 0 0 0 2 : 1.3% : C25 Nose, sinuses etc. 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C30-Larynx 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C32

C31

Trachea,Bronchus,Lung 3 : 0 : 0 0 0 0 0 0 0 0 0 0 1 1 0 1 : 1.3% : C33-C34 Other Thoracic organs 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C37-C38 Bone 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C40-C41 Melanoma of Skin 4 : 0 : 0 0 0 0 0 0 0 0 0 0 0 1 0 3 : 1.7% : C43 Other Skin 103 : 2 : 0 0 0 0 0 1 3 1 6 8 6 11 9 56 : 44.6% : C44 Mesothelioma 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C45 Kaposi sarcoma 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C46 Connective,Soft tissue 1 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 1 : 0.4% : C47;Breast 55 : 0 : 0 0 0 0 0 0 0 1 4 7 6 6 4 27 : 23.8% : C50

C49

Vulva 2 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 2 : 0.9% : C51 Vagina 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C52 Cervix Uteri 2 : 0 : 0 0 0 0 0 0 0 0 1 0 0 1 0 0 : 0.9% : C53 Corpus Uteri 5 : 0 : 0 0 0 0 0 0 0 0 0 0 0 1 0 4 : 2.2% : C54 Uterus unspec. 2 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 2 : 0.9% : C55 Ovary 5 : 0 : 0 0 0 0 0 0 1 0 0 1 1 1 0 1 : 2.2% : C56 Other Female Genital 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C57 Placenta 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C58 Kidney 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C64 Renal Pelvis 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C65 Ureter 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C66 Bladder 4 : 0 : 0 0 0 0 0 0 0 0 0 0 2 0 0 2 : 1.7% : C67 Other Urinary organs 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C68 Eye 2 : 0 : 0 0 0 0 0 1 1 0 0 0 0 0 0 0 : 0.9% : C69 Brain, Nervous system 2 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 2 : 0.9% : C70-C72 Thyroid 2 : 0 : 0 0 0 0 0 1 0 1 0 0 0 0 0 0 : 0.9% : C73 Adrenal gland 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C74 Other Endocrine 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C75 Hodgkin disease 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C81 Non-Hodgkin lymphoma 5 : 0 : 0 0 0 0 0 0 1 1 0 0 0 1 0 2 : 2.2% : C82-Immunoproliferative dis. 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C88

C85

Multiple Myeloma 1 : 0 : 0 0 0 0 0 0 0 0 0 0 1 0 0 0 : 0.4% : C90 Lymphoid Leukaemia 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C91 Myeloid Leukaemia 1 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 1 : 0.4% : C92-C94 Leukaemia unspec. 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C95 Other & unspecified 8 : 0 : 0 0 0 0 0 0 0 0 0 1 0 0 1 6 : 3.5% : Other ================================================================================================================================== A LL SITES 231 : 3 : 0 0 0 0 0 3 7 4 11 17 19 25 17 125 :100.0% :

==================================================================================================================================

32


2006: All Zimbabweans: Males

2.8

2.8

2.8

4.2

5.4

5.4

5.4

11.6

12.9

19.9

0 5 10 15 20 25

LUNG

BLADDER

COLON

LIVER

OESOPHAGUS

EYE



PROSTATE

KAPOSI SARCOMA

SITE

PERCENTAGE

Figure 17

2006: All Zimbabweans: Females

2

2.1

2.2

3.4

4

4

7

10.8

12.9

29.4

0 5 10 15 20 25 30 35

LIVER

STOMACH

OESOPHAGUS

OVARY

EYE



KAPOSI SARCOMA

BREAST

CERVIX UTERI

SITE

PERCENTAGE

33

TABLE 7 AGE, SEX AND SITE DISTRIBUTION: 2006 MALE: ZIMBABWE ALL RACES


C08


C31


C49

Penis 9 : 1 : 0 0 0 0 0 0 0 1 0 0 1 2 0 4 : 0.5% : C60 Prostate 238 : 6 : 0 0 0 0 0 0 1 1 1 5 8 14 27 175 : 12.9% : C61 Testis 2 : 0 : 0 0 0 0 0 0 0 1 1 0 0 0 0 0 : 0.1% : C62 Other male genital 2 : 0 : 0 0 0 0 0 1 0 1 0 0 0 0 0 0 : 0.1% : C63 Kidney 29 : 0 : 13 1 1 0 0 0 1 0 1 2 2 4 2 2 : 1.6% : C64 Renal Pelvis 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C65 Ureter 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C66 Bladder 52 : 1 : 1 0 0 0 0 1 2 1 1 2 3 2 10 28 : 2.8% : C67 Other Urinary organs 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C68 Eye 100 : 9 : 14 2 0 0 0 2 12 21 19 5 8 2 1 5 : 5.4% : C69 Brain, Nervous system 24 : 0 : 3 2 2 4 0 3 1 0 0 0 3 0 1 5 : 1.3% : C70-Thyroid 9 : 0 : 0 0 0 0 0 0 1 0 0 2 1 0 2 3 : 0.5% : C73

C72

Adrenal gland 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C74 Other Endocrine 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C75 Hodgkin disease 6 : 0 : 0 1 3 1 0 0 0 0 0 0 0 0 0 1 : 0.3% : C81 Non-Hodgkin lymphoma 100 : 4 : 5 6 4 1 3 4 11 16 12 9 12 2 4 7 : 5.4% : C82-C85 Immunoproliferative dis. 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C88 Multiple Myeloma 8 : 0 : 0 0 0 0 0 0 1 0 2 0 2 0 0 3 : 0.4% : C90 Lymphoid Leukaemia 8 : 1 : 1 1 1 0 0 0 0 0 0 1 0 0 3 0 : 0.4% : C91 Myeloid Leukaemia 12 : 0 : 2 0 0 0 1 3 0 2 1 2 0 0 0 1 : 0.7% : C92-Leukaemia unspec. 9 : 0 : 0 1 3 0 0 0 0 1 0 0 0 0 0 4 : 0.5% : C95

C94

Other & unspecified 52 : 3 : 0 0 1 0 1 2 3 3 5 5 5 4 4 16 : 2.8% : Other = =================================================================================================================================

ALL SITES 1842 : 73 : 44 19 26 26 32 70 153 148 135 133 126 123 149 585 :100.0% : ==================================================================================================================================

34

TABLE 8 AGE, SEX AND SITE DISTRIBUTION: 2006 FEMALE: ZIMBABWE ALL RACES

NUMBER OF CASES BY AGE GROUP ================================================================================================================================== SITE All Age 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65+ % of ICD Ages Unk. - 4 - 9 -14 -19 -24 -29 -34 -39 -44 -49 -54 -59 -64 Total (10th) ================================================================================================================================== Lip 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C00 Tongue 5 : 1 : 0 0 0 0 0 0 0 0 0 0 0 1 0 3 : 0.2% : C01-C02 Mouth 6 : 3 : 0 0 0 0 0 0 0 0 0 0 0 1 0 2 : 0.3% : C03-C06 Salivary glands 5 : 0 : 0 0 0 0 0 0 1 0 1 0 1 0 0 2 : 0.2% : C07-C08 Tonsil 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C09 Other Oropharynx 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C10 Nasopharynx 4 : 0 : 0 0 1 1 0 0 1 0 0 0 0 1 0 0 : 0.2% : C11 Hypopharynx 3 : 0 : 0 0 0 0 0 0 0 0 0 0 0 2 0 1 : 0.1% : C12-C13 Pharynx unspec. 1 : 0 : 0 0 0 0 0 0 0 0 0 0 0 1 0 0 : 0.0% : C14 Oesophagus 52 : 2 : 0 0 0 0 0 0 2 2 3 1 5 6 7 24 : 2.2% : C15 Stomach 48 : 1 : 0 0 0 0 1 0 0 2 4 2 2 11 7 18 : 2.1% : C16 Small intestine 1 : 0 : 0 0 0 0 0 0 0 0 0 0 0 1 0 0 : 0.0% : C17 Colon 40 : 3 : 0 0 0 0 2 0 0 1 4 3 5 5 3 14 : 1.7% : C18 Rectum 34 : 0 : 0 0 0 1 0 3 1 3 2 10 4 2 0 8 : 1.5% : C19-C20 Anus 7 : 0 : 0 0 0 0 0 0 3 1 0 0 1 0 0 2 : 0.3% : C21 Liver 46 : 2 : 1 0 0 0 2 2 1 1 4 2 1 3 1 26 : 2.0% : C22 Gallbladder etc. 5 : 0 : 0 0 0 0 0 0 1 0 0 0 0 2 0 2 : 0.2% : C23-C24 Pancreas 20 : 0 : 0 0 0 0 0 0 1 0 0 0 4 4 2 9 : 0.9% : C25 Nose, sinuses etc. 11 : 1 : 0 0 1 0 1 1 1 0 2 2 0 0 1 1 : 0.5% : C30-C31 Larynx 5 : 0 : 0 0 0 0 0 0 0 1 2 0 0 0 0 2 : 0.2% : C32 Trachea,Bronchus,Lung 23 : 1 : 0 0 0 0 0 1 2 3 0 2 2 2 3 7 : 1.0% : C33-C34 Other Thoracic organs 1 : 1 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C37-C38 Bone 24 : 2 : 0 3 2 3 4 5 1 3 1 0 0 0 0 0 : 1.0% : C40-C41 Melanoma of Skin 19 : 2 : 0 0 0 0 1 0 0 0 1 1 0 3 1 10 : 0.8% : C43 Other Skin 163 : 13 : 0 0 0 1 4 3 6 5 10 9 15 14 13 70 : 7.0% : C44 Mesothelioma 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C45 Kaposi sarcoma 251 : 21 : 2 2 4 2 10 39 60 41 23 17 14 9 2 5 : 10.8% : C46 Connective,Soft tissue 21 : 1 : 2 0 2 0 3 0 4 1 0 1 2 1 2 2 : 0.9% : C47;C49 Breast 300 : 12 : 0 0 0 3 5 13 14 35 32 37 39 27 23 60 : 12.9% : C50 Vulva 16 : 0 : 0 0 0 0 0 2 1 2 0 1 3 2 2 3 : 0.7% : C51 Vagina 10 : 1 : 0 0 1 0 0 1 2 0 2 0 0 0 1 2 : 0.4% : C52 Cervix Uteri 685 : 62 : 0 0 0 0 3 15 61 65 73 93 80 65 61 107 : 29.4% : C53 Corpus Uteri 49 : 3 : 0 0 0 0 1 2 1 0 3 5 1 4 8 21 : 2.1% : C54 Uterus unspec. 16 : 0 : 0 0 0 0 0 0 0 1 0 2 1 2 4 6 : 0.7% : C55 Ovary 79 : 2 : 0 1 3 1 5 5 11 7 8 7 10 5 3 11 : 3.4% : C56 Other Female Genital 1 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 1 0 : 0.0% : C57 Placenta 17 : 1 : 0 0 0 0 5 2 2 1 1 1 3 1 0 0 : 0.7% : C58 Kidney 14 : 1 : 6 0 3 0 0 0 0 0 0 0 1 0 3 0 : 0.6% : C64 Renal Pelvis 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C65 Ureter 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C66 Bladder 36 : 1 : 0 0 0 1 0 0 0 3 2 4 6 3 1 15 : 1.5% : C67 Other Urinary organs 1 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 1 : 0.0% : C68 Eye 94 : 16 : 6 1 1 1 5 13 20 8 11 5 2 0 3 2 : 4.0% : C69 Brain, Nervous system 14 : 0 : 1 1 1 1 0 2 0 0 1 2 0 1 1 3 : 0.6% : C70-C72 Thyroid 24 : 0 : 0 0 0 0 0 2 2 4 2 2 2 4 1 5 : 1.0% : C73 Adrenal gland 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C74 Other Endocrine 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C75 Hodgkin disease 7 : 1 : 0 0 2 1 0 0 1 0 1 0 1 0 0 0 : 0.3% : C81 Non-Hodgkin lymphoma 94 : 9 : 0 2 3 2 1 9 13 14 9 8 8 7 3 6 : 4.0% : C82-C85 Immunoproliferative dis. 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C88 Multiple Myeloma 9 : 0 : 0 0 0 0 0 0 0 0 0 1 2 3 0 3 : 0.4% : C90 Lymphoid Leukaemia 11 : 0 : 0 4 2 0 1 0 0 0 0 0 0 3 1 0 : 0.5% : C91 Myeloid Leukaemia 6 : 1 : 0 1 0 1 0 0 1 0 0 0 0 0 0 2 : 0.3% : C92-C94 Leukaemia unspec. 1 : 0 : 0 0 0 0 0 0 0 0 1 0 0 0 0 0 : 0.0% : C95 Other & unspecified 54 : 2 : 2 1 0 2 3 0 2 0 1 4 2 4 10 21 : 2.3% : Other ================================================================================================================================== ALL SITES 2333 :166 : 20 16 26 21 57 120 216 204 204 222 217 200 168 476 :100.0% : ==================================================================================================================================

35


2006: Harare Blacks: Males

2.8

2.9

3.3

4.1

4.4

5.8

6.4

8

16.7

21.8

0 5 10 15 20 25

COLON

EYE

BLADDER

STOMACH

LUNG


OESOPHAGUS

LIVER

PROSTATE

KAPOSI SARCOMA

SITE

PERCENTAGE

Figure 19

2006: Harare Blacks: Females

2.4

2.4

2.8

3.4

3.4

4.2

4.6

11.9

13.4

28.7

0 5 10 15 20 25 30 35

CORPUS UTERI

BLADDER

LIVER

STOMACH

OESOPHAGUS

NON HODGKIN LYMPHOMA

OVARY

BREAST

KAPOSI SARCOMA

CERVIX UTERI

SITE

PERCENTAGE

36

TABLE 9 AGE, SEX AND SITE DISTRIBUTION: 2006 MALE: HARARE BLACKS


C08


C31


C49

Penis 2 : 0 : 0 0 0 0 0 0 0 0 0 0 1 0 0 1 : 0.3% : C60 Prostate 121 : 2 : 0 0 0 0 0 0 1 1 0 2 6 6 13 90 : 16.7% : C61 Testis 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C62 Other male genital 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C63 Kidney 9 : 0 : 6 0 0 0 0 0 1 0 0 0 0 1 0 1 : 1.2% : C64 Renal Pelvis 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C65 Ureter 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C66 Bladder 24 : 0 : 0 0 0 0 0 1 0 0 1 2 1 1 2 16 : 3.3% : C67 Other Urinary organs 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C68 Eye 21 : 0 : 4 0 0 0 0 0 1 6 4 1 3 1 0 1 : 2.9% : C69 Brain, Nervous system 11 : 0 : 2 1 2 2 0 2 0 0 0 0 2 0 0 0 : 1.5% : C70-Thyroid 3 : 0 : 0 0 0 0 0 0 0 0 0 1 0 0 1 1 : 0.4% : C73

C72

Adrenal gland 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C74 Other Endocrine 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C75 Hodgkin disease 3 : 0 : 0 1 2 0 0 0 0 0 0 0 0 0 0 0 : 0.4% : C81 Non-Hodgkin lymphoma 42 : 1 : 1 4 1 0 0 1 5 10 6 4 5 0 1 3 : 5.8% : C82-C85 Immunoproliferative dis. 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C88 Multiple Myeloma 6 : 0 : 0 0 0 0 0 0 1 0 1 0 2 0 0 2 : 0.8% : C90 Lymphoid Leukaemia 3 : 0 : 0 0 1 0 0 0 0 0 0 1 0 0 1 0 : 0.4% : C91 Myeloid Leukaemia 8 : 0 : 1 0 0 0 1 3 0 2 1 0 0 0 0 0 : 1.1% : C92-Leukaemia unspec. 3 : 0 : 0 0 0 0 0 0 0 1 0 0 0 0 0 2 : 0.4% : C95

C94

Other & unspecified 17 : 1 : 0 0 0 0 0 0 1 3 2 1 2 1 1 5 : 2.3% : Other = =================================================================================================================================

ALL SITES 724 : 10 : 14 10 11 10 10 29 59 73 56 54 55 50 47 236 :100.0% : ==================================================================================================================================

37

TABLE 10 AGE, SEX AND SITE DISTRIBUTION: 2006 FEMALE: HARARE BLACKS


C08


C31


C49

Vulva 6 : 0 : 0 0 0 0 0 1 0 1 0 0 1 1 1 1 : 0.7% : C51 Vagina 2 : 0 : 0 0 0 0 0 0 1 0 1 0 0 0 0 0 : 0.2% : C52 Cervix Uteri 253 : 4 : 0 0 0 0 3 6 23 34 26 44 22 20 26 45 : 28.7% : C53 Corpus Uteri 21 : 0 : 0 0 0 0 0 1 1 0 1 2 1 3 4 8 : 2.4% : C54 Uterus unspec. 10 : 0 : 0 0 0 0 0 0 0 1 0 1 1 2 2 3 : 1.1% : C55 Ovary 41 : 0 : 0 1 1 0 2 4 5 3 4 4 4 2 2 9 : 4.6% : C56 Other Female Genital 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C57 Placenta 5 : 1 : 0 0 0 0 1 1 1 0 1 0 0 0 0 0 : 0.6% : C58 Kidney 4 : 0 : 1 0 2 0 0 0 0 0 0 0 1 0 0 0 : 0.5% : C64 Renal Pelvis 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C65 Ureter 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C66 Bladder 21 : 0 : 0 0 0 1 0 0 0 1 1 2 4 2 0 10 : 2.4% : C67 Other Urinary organs 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C68 Eye 15 : 0 : 3 0 1 1 3 0 3 1 0 2 0 0 1 0 : 1.7% : C69 Brain, Nervous system 7 : 0 : 0 1 0 0 0 2 0 0 0 2 0 1 1 0 : 0.8% : C70-C72 Thyroid 12 : 0 : 0 0 0 0 0 0 1 2 1 1 1 2 1 3 : 1.4% : C73 Adrenal gland 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C74 Other Endocrine 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C75 Hodgkin disease 5 : 0 : 0 0 2 1 0 0 1 0 1 0 0 0 0 0 : 0.6% : C81 Non-Hodgkin lymphoma 37 : 1 : 0 1 2 0 0 4 3 4 4 5 6 3 3 1 : 4.2% : C82-Immunoproliferative dis. 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C88

C85

Multiple Myeloma 5 : 0 : 0 0 0 0 0 0 0 0 0 0 0 2 0 3 : 0.6% : C90 Lymphoid Leukaemia 5 : 0 : 0 1 2 0 0 0 0 0 0 0 0 1 1 0 : 0.6% : C91 Myeloid Leukaemia 2 : 0 : 0 0 0 1 0 0 0 0 0 0 0 0 0 1 : 0.2% : C92-C94 Leukaemia unspec. 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C95 Other & unspecified 24 : 0 : 1 1 0 0 3 0 1 0 0 3 1 1 4 9 : 2.7% : Other ================================================================================================================================== A LL SITES 883 : 16 : 7 6 16 5 27 49 82 91 75 101 80 78 71 179 :100.0% :

==================================================================================================================================

38


2006: Harare Non-Blacks: Males

1.7

2.3

2.3

2.3

2.8

4

4

5.1

16.5

44.9

0 10 20 30 40 5


LUNG

BLADDER

OESOPHAGUS


MELANOMA OF SKIN

RECTUM

COLON

PROSTATE


SITE

PERCENTAGE

0

Figure 21

2006: Harare Non-Blacks: Females

1.4

2.2

2.2

2.2

2.9

2.9

3.6

5

23

39.6

0 5 10 15 20 25 30 35 40 45

LUNG

MOUTH

PANCREAS

MELANOMA OF SKIN

CORPUS UTERI

BLADDER


COLON

BREAST


SITE

PERCENTAGE

39

TABLE 11 AGE, SEX AND SITE DISTRIBUTION: 2006 MALE: HARARE NON-BLACKS

NUMBER OF CASES BY AGE GROUP ================================================================================================================================== SITE All Age 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65+ % of ICD Ages Unk. - 4 - 9 -14 -19 -24 -29 -34 -39 -44 -49 -54 -59 -64 Total (10th) ================================================================================================================================== Lip 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C00 Tongue 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C01-C02 Mouth 1 : 0 : 0 0 0 0 0 0 0 0 0 0 0 1 0 0 : 0.6% : C03-C06 Salivary glands 1 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 1 : 0.6% : C07-C08 Tonsil 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C09 Other Oropharynx 1 : 0 : 0 0 0 0 0 0 0 0 0 0 0 1 0 0 : 0.6% : C10 Nasopharynx 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C11 Hypopharynx 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C12-C13 Pharynx unspec. 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C14 Oesophagus 4 : 0 : 0 0 0 0 0 0 0 0 0 0 0 1 1 2 : 2.3% : C15 Stomach 1 : 0 : 0 0 0 0 0 0 0 0 0 0 1 0 0 0 : 0.6% : C16 Small intestine 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C17 Colon 9 : 0 : 0 0 0 0 0 0 0 0 0 0 0 1 0 8 : 5.1% : C18 Rectum 7 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 3 4 : 4.0% : C19-Anus 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C21

C20

Liver 2 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 2 : 1.1% : C22 Gallbladder etc. 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C23-Pancreas 1 : 0 : 0 0 0 0 0 0 0 0 0 1 0 0 0 0 : 0.6% : C25

C24

Nose, sinuses etc. 1 : 0 : 0 0 0 0 0 0 0 0 0 0 1 0 0 0 : 0.6% : C30-C31 Larynx 1 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 1 0 : 0.6% : C32 Trachea,Bronchus,Lung 4 : 0 : 0 0 0 0 0 0 0 0 0 1 1 0 1 1 : 2.3% : C33-C34 Other Thoracic organs 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C37-C38 Bone 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C40-Melanoma of Skin 7 : 0 : 0 0 0 0 0 0 0 0 0 2 1 0 1 3 : 4.0% : C43

C41

Other Skin 79 : 0 : 0 0 0 0 1 1 2 3 1 5 7 10 16 33 : 44.9% : C44 Mesothelioma 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C45 Kaposi sarcoma 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C46 Connective,Soft tissue 2 : 0 : 0 0 0 0 0 0 0 0 0 0 0 1 0 1 : 1.1% : C47;C49 Breast 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C50 Penis 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C60 Prostate 29 : 0 : 0 0 0 0 0 0 0 0 0 1 0 1 1 26 : 16.5% : C61 Testis 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C62 Other male genital 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C63 Kidney 3 : 0 : 0 0 0 0 0 0 0 0 0 1 0 0 1 1 : 1.7% : C64 Renal Pelvis 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C65 Ureter 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C66 Bladder 4 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 1 3 : 2.3% : C67 Other Urinary organs 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C68 Eye 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C69 Brain, Nervous system 3 : 0 : 0 0 0 0 0 0 0 0 0 0 1 0 1 1 : 1.7% : C70-C72 Thyroid 1 : 0 : 0 0 0 0 0 0 0 0 0 0 1 0 0 0 : 0.6% : C73 Adrenal gland 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C74 Other Endocrine 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C75 Hodgkin disease 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C81 Non-Hodgkin lymphoma 5 : 0 : 0 0 0 0 1 0 0 0 0 1 1 0 0 2 : 2.8% : C82-C85 Immunoproliferative dis. 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C88 Multiple Myeloma 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C90 Lymphoid Leukaemia 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C91 Myeloid Leukaemia 1 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 1 : 0.6% : C92-C94 Leukaemia unspec. 2 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 2 : 1.1% : C95 Other & unspecified 7 : 0 : 0 0 0 0 0 0 0 0 0 2 0 0 0 5 : 4.0% : Other ================================================================================================================================== ALL SITES 176 : 0 : 0 0 0 0 2 1 2 3 1 14 14 16 27 96 :100.0% : ==================================================================================================================================

40

TABLE 12 AGE, SEX AND SITE DISTRIBUTION: 2006 FEMALE: HARARE NON-BLACKS

NUMBER OF CASES BY AGE GROUP ================================================================================================================================== SITE All Age 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65+ % of ICD Ages Unk. - 4 - 9 -14 -19 -24 -29 -34 -39 -44 -49 -54 -59 -64 Total (10th) ================================================================================================================================== Lip 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C00 Tongue 3 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 3 : 2.2% : C01-C02 Mouth 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C03-C06 Salivary glands 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C07-C08 Tonsil 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C09 Other Oropharynx 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C10 Nasopharynx 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C11 Hypopharynx 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C12-C13 Pharynx unspec. 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C14 Oesophagus 2 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 2 : 1.4% : C15 Stomach 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C16 Small intestine 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C17 Colon 7 : 0 : 0 0 0 0 0 0 0 0 0 0 1 0 1 5 : 5.0% : C18 Rectum 1 : 0 : 0 0 0 0 0 0 0 0 0 0 1 0 0 0 : 0.7% : C19-C20 Anus 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C21 Liver 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C22 Gallbladder etc. 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C23-C24 Pancreas 3 : 0 : 0 0 0 0 0 0 1 0 0 0 0 0 0 2 : 2.2% : C25 Nose, sinuses etc. 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C30-C31 Larynx 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C32 Trachea,Bronchus,Lung 2 : 0 : 0 0 0 0 0 0 0 0 0 0 1 1 0 0 : 1.4% : C33-C34 Other Thoracic organs 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C37-C38 Bone 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C40-C41 Melanoma of Skin 3 : 0 : 0 0 0 0 0 0 0 0 0 0 0 1 0 2 : 2.2% : C43 Other Skin 55 : 1 : 0 0 0 0 0 0 2 1 4 3 3 4 4 33 : 39.6% : C44 Mesothelioma 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C45 Kaposi sarcoma 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C46 Connective,Soft tissue 1 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 1 : 0.7% : C47;C49 Breast 32 : 0 : 0 0 0 0 0 0 0 1 2 4 5 4 1 15 : 23.0% : C50 Vulva 2 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 2 : 1.4% : C51 Vagina 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C52 Cervix Uteri 1 : 0 : 0 0 0 0 0 0 0 0 1 0 0 0 0 0 : 0.7% : C53 Corpus Uteri 4 : 0 : 0 0 0 0 0 0 0 0 0 0 0 1 0 3 : 2.9% : C54 Uterus unspec. 1 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 1 : 0.7% : C55 Ovary 2 : 0 : 0 0 0 0 0 0 0 0 0 0 0 1 0 1 : 1.4% : C56 Other Female Genital 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C57 Placenta 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C58 Kidney 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C64 Renal Pelvis 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C65 Ureter 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C66 Bladder 4 : 0 : 0 0 0 0 0 0 0 0 0 0 2 0 0 2 : 2.9% : C67 Other Urinary organs 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C68 Eye 2 : 0 : 0 0 0 0 0 1 1 0 0 0 0 0 0 0 : 1.4% : C69 Brain, Nervous system 2 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 2 : 1.4% : C70-C72 Thyroid 1 : 0 : 0 0 0 0 0 0 0 1 0 0 0 0 0 0 : 0.7% : C73 Adrenal gland 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C74 Other Endocrine 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C75 Hodgkin disease 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C81 Non-Hodgkin lymphoma 5 : 0 : 0 0 0 0 0 0 1 1 0 0 0 1 0 2 : 3.6% : C82-Immunoproliferative dis. 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C88

C85


Other

A LL SITES 139 : 1 : 0 0 0 0 0 1 5 4 7 8 14 13 6 80 :100.0% :

==================================================================================================================================

41


2006: Harare All Races: Males

3.1

3.2

3.4

4

5.2

5.6

6.7

9.7

16.7

17.6

0 5 10 15 20

BLADDER

COLON

STOMACH

LUNG

NON HODGKIN LYMPHOMA

OESOPHAGUS

LIVER


PROSTATE

KAPOSI SARCOMA

SITE

PERCENTAGE

Figure 23

2006: Harare All Races: Females

2.4

2.4

2.9

3.1

4.1

4.2

6.5

11.5

13.4

24.9

0 5 10 15 20 25 30

CORPUS UTERI

LIVER

STOMACH

OESOPHAGUS


OVARY


KAPOSI SARCOMA

BREAST

CERVIX UTERI

SITE

PERCENTAGE

42

TABLE 13 AGE, SEX AND SITE DISTRIBUTION: 2006 MALE: HARARE ALL RACES

NUMBER OF CASES BY AGE GROUP ================================================================================================================================== SITE All Age 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65+ % of ICD Ages Unk. - 4 - 9 -14 -19 -24 -29 -34 -39 -44 -49 -54 -59 -64 Total (10th) ================================================================================================================================== Lip 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C00 Tongue 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C01-C02 Mouth 4 : 0 : 0 0 0 0 0 1 0 0 0 1 0 2 0 0 : 0.4% : C03-C06 Salivary glands 4 : 0 : 0 1 0 0 0 0 0 0 0 1 0 1 0 1 : 0.4% : C07-C08 Tonsil 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C09 Other Oropharynx 1 : 0 : 0 0 0 0 0 0 0 0 0 0 0 1 0 0 : 0.1% : C10 Nasopharynx 2 : 1 : 0 0 0 0 0 0 0 0 0 0 0 0 0 1 : 0.2% : C11 Hypopharynx 1 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 1 : 0.1% : C12-C13 Pharynx unspec. 1 : 0 : 0 0 0 0 0 0 0 0 1 0 0 0 0 0 : 0.1% : C14 Oesophagus 50 : 0 : 0 0 0 0 1 0 1 3 2 5 3 5 2 28 : 5.6% : C15 Stomach 31 : 0 : 0 0 0 0 0 1 1 2 2 3 3 5 0 14 : 3.4% : C16 Small intestine 2 : 0 : 0 0 0 0 0 0 0 0 0 0 0 1 1 0 : 0.2% : C17 Colon 29 : 0 : 0 0 0 0 0 0 0 1 0 3 2 5 2 16 : 3.2% : C18 Rectum 23 : 0 : 0 0 0 0 1 1 1 0 3 0 0 1 7 9 : 2.6% : C19-Anus 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C21

C20

Liver 60 : 0 : 0 0 1 1 1 6 4 4 7 5 5 1 8 17 : 6.7% : C22 Gallbladder etc. 2 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 2 : 0.2% : C23-Pancreas 12 : 0 : 0 0 0 0 0 0 0 0 0 3 1 0 1 7 : 1.3% : C25

C24

Nose, sinuses etc. 6 : 0 : 0 0 0 0 0 1 0 2 0 1 1 1 0 0 : 0.7% : C30-C31 Larynx 15 : 0 : 0 0 0 0 0 0 0 0 0 3 2 4 1 5 : 1.7% : C32 Trachea,Bronchus,Lung 36 : 0 : 0 0 0 0 0 0 2 1 3 2 3 7 3 15 : 4.0% : C33-C34 Other Thoracic organs 2 : 0 : 0 0 0 0 1 0 0 0 0 0 0 0 0 1 : 0.2% : C37-C38 Bone 19 : 0 : 0 1 1 4 2 3 1 0 1 1 2 0 1 2 : 2.1% : C40-Melanoma of Skin 13 : 0 : 0 0 0 0 0 0 1 0 0 2 1 0 3 6 : 1.4% : C43

C41

Other Skin 87 : 1 : 0 0 0 0 1 1 3 4 4 6 7 10 16 34 : 9.7% : C44 Mesothelioma 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C45 Kaposi sarcoma 158 : 4 : 0 2 2 2 2 7 37 36 18 15 14 10 5 4 : 17.6% : C46 Connective,Soft tissue 11 : 0 : 0 0 1 1 1 2 0 0 1 0 0 1 0 4 : 1.2% : C47;C49 Breast 3 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 1 2 : 0.3% : C50 Penis 2 : 0 : 0 0 0 0 0 0 0 0 0 0 1 0 0 1 : 0.2% : C60 Prostate 150 : 2 : 0 0 0 0 0 0 1 1 0 3 6 7 14 116 : 16.7% : C61 Testis 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C62 Other male genital 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C63 Kidney 12 : 0 : 6 0 0 0 0 0 1 0 0 1 0 1 1 2 : 1.3% : C64 Renal Pelvis 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C65 Ureter 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C66 Bladder 28 : 0 : 0 0 0 0 0 1 0 0 1 2 1 1 3 19 : 3.1% : C67 Other Urinary organs 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C68 Eye 21 : 0 : 4 0 0 0 0 0 1 6 4 1 3 1 0 1 : 2.3% : C69 Brain, Nervous system 14 : 0 : 2 1 2 2 0 2 0 0 0 0 3 0 1 1 : 1.6% : C70-C72 Thyroid 4 : 0 : 0 0 0 0 0 0 0 0 0 1 1 0 1 1 : 0.4% : C73 Adrenal gland 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C74 Other Endocrine 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C75 Hodgkin disease 3 : 0 : 0 1 2 0 0 0 0 0 0 0 0 0 0 0 : 0.3% : C81 Non-Hodgkin lymphoma 47 : 1 : 1 4 1 0 1 1 5 10 6 5 6 0 1 5 : 5.2% : C82-C85 Immunoproliferative dis. 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C88 Multiple Myeloma 6 : 0 : 0 0 0 0 0 0 1 0 1 0 2 0 0 2 : 0.7% : C90 Lymphoid Leukaemia 3 : 0 : 0 0 1 0 0 0 0 0 0 1 0 0 1 0 : 0.3% : C91 Myeloid Leukaemia 9 : 0 : 1 0 0 0 1 3 0 2 1 0 0 0 0 1 : 1.0% : C92-C94 Leukaemia unspec. 5 : 0 : 0 0 0 0 0 0 0 1 0 0 0 0 0 4 : 0.6% : C95 Other & unspecified 24 : 1 : 0 0 0 0 0 0 1 3 2 3 2 1 1 10 : 2.7% : Other ================================================================================================================================== ALL SITES 900 : 10 : 14 10 11 10 12 30 61 76 57 68 69 66 74 332 :100.0% : ==================================================================================================================================

43

TABLE 14 AGE, SEX AND SITE DISTRIBUTION: 2006 FEMALE: HARARE ALL RACES

NUMBER OF CASES BY AGE GROUP ================================================================================================================================== SITE All Age 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65+ % of ICD Ages Unk. - 4 - 9 -14 -19 -24 -29 -34 -39 -44 -49 -54 -59 -64 Total (10th) ================================================================================================================================== Lip 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C00 Tongue 3 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 3 : 0.3% : C01-C02 Mouth 3 : 1 : 0 0 0 0 0 0 0 0 0 0 0 0 0 2 : 0.3% : C03-C06 Salivary glands 2 : 0 : 0 0 0 0 0 0 1 0 0 0 1 0 0 0 : 0.2% : C07-C08 Tonsil 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C09 Other Oropharynx 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C10 Nasopharynx 2 : 0 : 0 0 1 0 0 0 1 0 0 0 0 0 0 0 : 0.2% : C11 Hypopharynx 1 : 0 : 0 0 0 0 0 0 0 0 0 0 0 1 0 0 : 0.1% : C12-C13 Pharynx unspec. 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C14 Oesophagus 32 : 0 : 0 0 0 0 0 0 1 1 1 1 4 5 4 15 : 3.1% : C15 Stomach 30 : 0 : 0 0 0 0 1 0 0 0 4 1 2 6 5 11 : 2.9% : C16 Small intestine 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C17 Colon 24 : 0 : 0 0 0 0 1 0 0 0 3 1 4 3 3 9 : 2.3% : C18 Rectum 13 : 0 : 0 0 0 0 0 2 1 1 0 4 3 0 0 2 : 1.3% : C19-C20 Anus 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C21 Liver 25 : 0 : 0 0 0 0 0 1 0 0 1 2 1 3 1 16 : 2.4% : C22 Gallbladder etc. 4 : 0 : 0 0 0 0 0 0 1 0 0 0 0 2 0 1 : 0.4% : C23-C24 Pancreas 14 : 0 : 0 0 0 0 0 0 1 0 0 0 3 1 1 8 : 1.4% : C25 Nose, sinuses etc. 3 : 0 : 0 0 1 0 0 0 0 0 0 1 0 0 1 0 : 0.3% : C30-C31 Larynx 2 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 2 : 0.2% : C32 Trachea,Bronchus,Lung 14 : 1 : 0 0 0 0 0 0 1 2 0 1 1 2 1 5 : 1.4% : C33-C34 Other Thoracic organs 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C37-C38 Bone 8 : 0 : 0 0 1 0 2 3 0 1 1 0 0 0 0 0 : 0.8% : C40-C41 Melanoma of Skin 7 : 0 : 0 0 0 0 1 0 0 0 0 0 0 2 0 4 : 0.7% : C43 Other Skin 66 : 1 : 0 0 0 0 1 0 2 2 5 3 7 4 5 36 : 6.5% : C44 Mesothelioma 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C45 Kaposi sarcoma 118 : 6 : 1 1 2 0 4 22 29 19 12 8 7 5 0 2 : 11.5% : C46 Connective,Soft tissue 9 : 0 : 1 0 1 0 2 0 1 0 0 0 1 0 1 2 : 0.9% : C47;C49 Breast 137 : 2 : 0 0 0 1 3 2 6 20 14 20 15 14 9 31 : 13.4% : C50 Vulva 8 : 0 : 0 0 0 0 0 1 0 1 0 0 1 1 1 3 : 0.8% : C51 Vagina 2 : 0 : 0 0 0 0 0 0 1 0 1 0 0 0 0 0 : 0.2% : C52 Cervix Uteri 254 : 4 : 0 0 0 0 3 6 23 34 27 44 22 20 26 45 : 24.9% : C53 Corpus Uteri 25 : 0 : 0 0 0 0 0 1 1 0 1 2 1 4 4 11 : 2.4% : C54 Uterus unspec. 11 : 0 : 0 0 0 0 0 0 0 1 0 1 1 2 2 4 : 1.1% : C55 Ovary 43 : 0 : 0 1 1 0 2 4 5 3 4 4 4 3 2 10 : 4.2% : C56 Other Female Genital 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C57 Placenta 5 : 1 : 0 0 0 0 1 1 1 0 1 0 0 0 0 0 : 0.5% : C58 Kidney 4 : 0 : 1 0 2 0 0 0 0 0 0 0 1 0 0 0 : 0.4% : C64 Renal Pelvis 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C65 Ureter 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C66 Bladder 25 : 0 : 0 0 0 1 0 0 0 1 1 2 6 2 0 12 : 2.4% : C67 Other Urinary organs 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C68 Eye 17 : 0 : 3 0 1 1 3 1 4 1 0 2 0 0 1 0 : 1.7% : C69 Brain, Nervous system 9 : 0 : 0 1 0 0 0 2 0 0 0 2 0 1 1 2 : 0.9% : C70-C72 Thyroid 13 : 0 : 0 0 0 0 0 0 1 3 1 1 1 2 1 3 : 1.3% : C73 Adrenal gland 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C74 Other Endocrine 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C75 Hodgkin disease 5 : 0 : 0 0 2 1 0 0 1 0 1 0 0 0 0 0 : 0.5% : C81 Non-Hodgkin lymphoma 42 : 1 : 0 1 2 0 0 4 4 5 4 5 6 4 3 3 : 4.1% : C82-Immunoproliferative dis. 0 : 0 : 0 0 0 0 0 0 0 0 0 0 0 0 0 0 : 0.0% : C88

C85


Other

A LL SITES 1022 : 17 : 7 6 16 5 27 50 87 95 82 109 94 91 77 259 :100.0% :

==================================================================================================================================

44


2006: Paediatrics: Boys

2.2

2.4

3.4

4.5

7.9

10.1

12.4

16.9

16.9

18

0 5 10 15 20


CONNECTIVE, SOFT TISSUE

BONE

HODGKIN DISEASE


LEUKAEMIA

KAPOSI SARCOMA


WILMS TUMOUR

RETINOBLASTOMA

SITE

PERCENTAGE

Figure 25

2006: Paediatrics: Girls

3.2

4.8

6.5

6.5

8.1

8.1

11.3

12.9

12.9

14.5

0 2 4 6 8 10 12 14 16

HODGKIN DISEASE


CONNECTIVE, SOFT TISSUE

OVARY

BONE


LEUKAEMIA

RETINOBLASTOMA

KAPOSI SARCOMA

WILMS TUMOUR

SITE

PERCENTAGE

45

2006 annual report - wordpress.com...introduction the zimbabwe cancer registry (zcr) is pleased to...

Documents